Introduction
(S)-Amlodipine, clinically known as Levamlodipine, is the pharmacologically active S-enantiomer of racemic amlodipine—a highly selective, long-acting dihydropyridine calcium channel blocker (DHP-CCB). As a core oral pharmaceutical raw material for cardiovascular disease management, it has twice the pharmacological potency of the racemic amlodipine mixture, with a significantly lower incidence of dose-related adverse reactions (e.g., peripheral edema). Its chemical formula is C₂₀H₂₅ClN₂O₅, and it is clinically formulated into low-dose oral tablets (2.5 mg, 5 mg) as the standard specification. Characterized by ultra-high oral bioavailability (~90%), no first-pass hepatic metabolism, and an extremely long elimination half-life (35–50 hours), it achieves sustained 24-hour therapeutic effects with once-daily administration, and its absorption is completely unaffected by food intake. With minimal depressant effects on myocardial contractility and cardiac conduction, it is a first-line clinical agent for hypertension and angina pectoris, widely used in cardiology, geriatrics, and general internal medicine for long-term cardiovascular disease management in adults and the elderly.
Core Pharmacological Mechanism (to support its therapeutic uses)
(S)-Amlodipine exerts its antihypertensive and antianginal effects through highly selective inhibition of L-type voltage-gated calcium channels predominantly expressed on the cell membranes of vascular smooth muscle cells (VSMCs)—especially those in peripheral resistance arterioles and coronary arteries. It has almost no affinity for calcium channels in cardiac myocytes, sinoatrial nodes, or atrioventricular nodes, which is the key to its minimal cardiac side effects.
The drug reversibly binds to the hydrophobic domain of the α1 subunit of the L-type calcium channel, blocking the influx of extracellular calcium ions into VSMCs and reducing intracellular calcium ion concentration. This leads to the relaxation of contracted vascular smooth muscle, which further produces two core therapeutic effects:
Antihypertensive effect: Dilatation of peripheral resistance arterioles reduces systemic vascular resistance (SVR) in a dose-dependent manner, lowering arterial blood pressure steadily. Its gradual onset of action (the maximum therapeutic effect is achieved after 7–14 days of continuous administration) avoids abrupt blood pressure drops and reflex tachycardia—a common limitation of short-acting DHPs.
Antianginal effect: A dual action of reducing myocardial oxygen demand and increasing myocardial oxygen supply. It lowers cardiac afterload by dilating peripheral blood vessels, thus reducing the contractile load of the heart and myocardial oxygen consumption; at the same time, it dilates stenotic, spastic coronary arteries (including epicardial large vessels and small coronary resistance vessels), increasing coronary blood flow and improving perfusion to ischemic myocardial tissue.
In addition, (S)-Amlodipine has mild renal protective effects: it dilates the afferent arterioles of renal glomeruli, increases renal blood flow without damaging the glomerular filtration barrier, making it safe for hypertensive patients with mild to moderate chronic kidney disease (CKD). It also has no significant impact on blood glucose, lipid metabolism, or serum electrolyte levels, which is an important advantage for hypertensive patients complicated with type 2 diabetes or dyslipidemia.
Primary Therapeutic Uses
(S)-Amlodipine is clinically indicated as a first-line drug for the treatment of essential hypertension and angina pectoris (chronic stable and vasospastic types) in adults. It is suitable for both monotherapy and combination therapy, with definite curative effects and proven clinical benefits in reducing major adverse cardiovascular events (MACEs) such as myocardial infarction and stroke. Its specific clinical applications are as follows:
1. Essential Hypertension (all types and severities)
It is the preferred monotherapy for mild to moderate essential hypertension in adults and the elderly, and can be combined with other first-line antihypertensive drugs (angiotensin II receptor blockers/ARBs, ACE inhibitors, thiazide diuretics, beta-blockers) for the treatment of severe or refractory hypertension that cannot be controlled by a single drug.
It is particularly suitable for special hypertensive populations: elderly patients with isolated systolic hypertension (the most common type of geriatric hypertension), hypertensive patients complicated with coronary heart disease/angina pectoris, hypertensive patients with type 2 diabetes or mild to moderate CKD (eGFR ≥30 mL/min/1.73m²), and patients with hypertension and left ventricular hypertrophy. Its 24-hour sustained blood pressure-lowering effect can effectively control morning surge hypertension—a high-risk period for cardiovascular events—and significantly improve long-term blood pressure control compliance.
2. Chronic Stable Angina Pectoris
It is used as monotherapy or adjuvant therapy (combined with nitrates, beta-blockers) for adult patients with chronic stable angina. It can effectively reduce the frequency of angina attacks and the dosage of sublingual nitroglycerin for acute relief, improve exercise tolerance and daily quality of life, and is suitable for long-term secondary prevention of stable coronary heart disease.
3. Vasospastic Angina (Prinzmetal’s Angina)
It is the first-line specific therapeutic agent for vasospastic angina, a type of angina caused by spontaneous coronary artery spasm at rest. Its selective coronary vasodilatory effect can directly reverse coronary artery spasm, eliminate myocardial ischemia, and prevent the recurrence of angina attacks. Unlike beta-blockers (which may aggravate coronary spasm), it is the gold standard for monotherapy of this type of angina.
4. Adjuvant Therapy for Coronary Artery Disease (CAD) with normal blood pressure
For adult patients with diagnosed CAD (e.g., post-percutaneous coronary intervention/PCI or coronary artery bypass grafting/CABG) and normal baseline blood pressure, low-dose (S)-Amlodipine can improve coronary microcirculation perfusion, reduce the risk of myocardial ischemia and silent myocardial infarction, and is a clinically recommended adjuvant drug for the long-term secondary prevention of CAD.
Clinical Application Key Points
(S)-Amlodipine has the characteristics of low-dose administration, good tolerability, and simple medication regimen, but its clinical use requires gradual dose titration and individualized treatment, especially for special populations such as the elderly and patients with organ insufficiency. The key application points are as follows:
1. Administration and Dosage
Oral administration, once daily, can be taken at any time of the day (with or without food); the tablet can be swallowed whole or crushed for patients with swallowing difficulties.
Adults: The standard starting dose is 2.5 mg once daily; the dose can be titrated to 5 mg once daily after 7–14 days according to blood pressure/angina control and patient tolerability (5 mg is the maximum daily dose for most patients).
Special populations: For elderly patients (≥65 years old), patients with mild to moderate hepatic insufficiency or mild to moderate renal insufficiency, the starting dose is recommended to be 2.5 mg once daily (no further dose reduction is required for mild to moderate renal insufficiency, as the drug is mainly metabolized by the liver).
2. Main Adverse Reactions
Adverse reactions are mild, transient, and dose-related, with an overall incidence of <10% (significantly lower than racemic amlodipine). The most common reactions are mild vasodilation-related symptoms: peripheral edema (mostly mild lower limb edema, occurring in <5% of patients), facial flushing, headache, and dizziness. These symptoms mostly appear at the initial stage of treatment and resolve spontaneously with the body’s adaptation to the drug.
Other rare mild adverse reactions include palpitations, fatigue, gingival hyperplasia (slow onset, reversible after drug withdrawal), and mild gastrointestinal discomfort (nausea, abdominal distension). Severe adverse reactions (severe hypotension, acute myocardial infarction, cardiac arrhythmia) are extremely rare and mostly associated with improper combined medication or underlying severe cardiovascular diseases.
3. Contraindications
Contraindicated in patients with:
Hypersensitivity to (S)-Amlodipine, other dihydropyridine CCBs, or any component of the pharmaceutical preparation;
Severe hypotension (systolic blood pressure <90 mmHg);
Cardiogenic shock (caused by acute myocardial infarction, severe heart failure, etc.);
Unstable angina pectoris (except vasospastic angina) in the acute phase without close clinical monitoring.
4. Key Precautions
Gradual onset of action: The maximum therapeutic effect is achieved after 7–14 days of continuous administration; do not adjust the dose too frequently to avoid inaccurate efficacy evaluation.
Severe hepatic insufficiency: For patients with severe hepatic insufficiency (Child-Pugh C grade), the dose should be reduced and blood pressure/liver function should be closely monitored (the drug is mainly metabolized in the liver).
Pregnancy and lactation: Use with extreme caution; the drug can pass through the placental barrier and be excreted in breast milk, and is only used when the therapeutic benefit outweighs the potential risk to the fetus/infant (no sufficient clinical safety data for pregnant women).
Driving and operating machinery: Mild dizziness or fatigue may occur at the beginning of treatment; avoid engaging in high-risk operations until the body adapts to the drug.
Avoid abrupt withdrawal: Long-term use should not be abruptly discontinued to prevent rebound hypertension or aggravated angina pectoris; the dose can be gradually reduced if drug withdrawal is necessary.
5. Drug Interactions
(S)-Amlodipine has a very low risk of drug-drug interactions because it undergoes minimal metabolism by hepatic cytochrome P450 enzymes and does not induce or inhibit key isoenzymes (e.g., CYP3A4, CYP2C9). The main interactions are synergistic therapeutic effects with other cardiovascular drugs:
Antihypertensive drugs: Combined use with ARBs, ACE inhibitors, thiazide diuretics, or beta-blockers produces a synergistic antihypertensive effect; the dose of each drug can be appropriately reduced to lower the risk of adverse reactions.
Antianginal drugs: Combined use with nitrates (isosorbide dinitrate, nitroglycerin) enhances coronary vasodilation and antianginal effects; combined use with beta-blockers offsets the mild tachycardia that may occur in individual patients and more effectively reduces myocardial oxygen demand.
Lipid-lowering drugs: No significant interaction with statins (atorvastatin, rosuvastatin); combined use is safe and effective for hypertensive patients with dyslipidemia and coronary heart disease.
Antidiabetic drugs: No interference with the efficacy of oral hypoglycemic agents or insulin; suitable for long-term use in hypertensive patients with type 2 diabetes.
FAQ
Q1. Can I get a free sample?
We can send you a samll free sample, and you only need to pay for the shipping cost.
Q2. What is the HyperChem payment term?
T/T in advance
LC at sight
DP at sight
Bank transfer
PayPal
Bitcoin...
Q3. What is HyperChem shipment policy?
Our policy is to strive for the quickest shipment time possible.
For ready stock samples, they are usually shipped within 3 working days after payment received.
For non-ready stock, please contact HyperChem sales team to negotiate.
Q4. What is HyperChem shipment term?
By Express
FedEx UPS DHL EMS
Fast: 3-7 days around, high cost, door to door service
By Air
Suitable for more than 50kg
Fast: 3-7 days, hight cost, port to port, professional broker needed
By Sea
Suitable for more than 500kg
Fast: 7-45 days, low cost, port to port, professional broker needed
We will always attempt to utilize the quickest and most affordable way for customers to receive orders. And follow -up with customers via email for all shipment details as well as updated track information until it arrives without damage.
Q5. What HyperChem will provide after shipment?
For sample orders:
After shipment is done, an timely email including:
1. Track details (Fedex /TNT/DHL/EMS Track number)
2. Packaging photo
3. COA, MSDS, etc
4. Dispatch date & Estimated arriving time
5. Shipping invoice
For commercial orders:
A full set of shipment documents as well as package photos can be provided in scan-copy and original, to help customers complete the customs clearance process.
